Cara Therapeutic EBITDA vs. Shares Outstanding
| CARA Stock | USD 0.31 0.01 3.33% |
EBITDA | First Reported 2010-12-31 | Previous Quarter -117.7 M | Current Value -111.8 M | Quarterly Volatility 45.3 M |
For Cara Therapeutic profitability analysis, we use financial ratios and fundamental drivers that measure the ability of Cara Therapeutic to generate income relative to revenue, assets, operating costs, and current equity. These fundamental indicators attest to how well Cara Therapeutic utilizes its assets to generate profit and value for its shareholders. The profitability module also shows relationships between Cara Therapeutic's most relevant fundamental drivers. It provides multiple suggestions of what could affect the performance of Cara Therapeutic over time as well as its relative position and ranking within its peers.
Cara |
Is Pharmaceuticals space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Cara Therapeutic. If investors know Cara will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Cara Therapeutic listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.75) | Revenue Per Share 0.202 | Quarterly Revenue Growth (0.86) | Return On Assets (0.63) | Return On Equity (1.84) |
The market value of Cara Therapeutic is measured differently than its book value, which is the value of Cara that is recorded on the company's balance sheet. Investors also form their own opinion of Cara Therapeutic's value that differs from its market value or its book value, called intrinsic value, which is Cara Therapeutic's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Cara Therapeutic's market value can be influenced by many factors that don't directly affect Cara Therapeutic's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Cara Therapeutic's value and its price as these two are different measures arrived at by different means. Investors typically determine if Cara Therapeutic is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Cara Therapeutic's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cara Therapeutic Shares Outstanding vs. EBITDA Fundamental Analysis
Comparative valuation techniques use various fundamental indicators to help in determining Cara Therapeutic's current stock value. Our valuation model uses many indicators to compare Cara Therapeutic value to that of its competitors to determine the firm's financial worth. Cara Therapeutic is number one stock in ebitda category among its peers. It also is number one stock in shares outstanding category among its peers . At present, Cara Therapeutic's EBITDA is projected to decrease significantly based on the last few years of reporting. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Cara Therapeutic's earnings, one of the primary drivers of an investment's value.Cara Shares Outstanding vs. EBITDA
EBITDA stands for earnings before interest, taxes, depreciation, and amortization. It is a measure of a company operating cash flow based on data from the company income statement and is a very good way to compare companies within industries or across different sectors. However, unlike Operating Cash Flow, EBITDA does not include the effects of changes in working capital.
Cara Therapeutic |
| = | (117.65 M) |
In a nutshell, EBITDA is calculated by adding back each of the excluded items to the post-tax profit, and can be used to compare companies with very different capital structures.
Outstanding Shares are shares of common stock of a public company that were purchased by investors after they were authorized and issued by the company to the public. Outstanding Shares are typically reported on fully diluted basis, including exotic instruments such as options, or convertibles bonds.
Cara Therapeutic |
| = | 54.86 M |
Outstanding shares that are stated on company Balance Sheet are used when calculating many important valuation and performance indicators including Return on Equity, Market Cap, EPS and many others.
Cara Shares Outstanding Comparison
Cara Therapeutic is currently under evaluation in shares outstanding category among its peers.
Cara Therapeutic Profitability Projections
The most important aspect of a successful company is its ability to generate a profit. For investors in Cara Therapeutic, profitability is also one of the essential criteria for including it into their portfolios because, without profit, Cara Therapeutic will eventually generate negative long term returns. The profitability progress is the general direction of Cara Therapeutic's change in net profit over the period of time. It can combine multiple indicators of Cara Therapeutic, where stable trends show no significant progress. An accelerating trend is seen as positive, while a decreasing one is unfavorable. A rising trend means that profits are rising, and operational efficiency may be rising as well. A decreasing trend is a sign of poor performance and may indicate upcoming losses.
| Last Reported | Projected for Next Year | ||
| Accumulated Other Comprehensive Income | -260 K | -273 K | |
| Operating Income | -121.5 M | -115.4 M | |
| Income Before Tax | -118.5 M | -112.6 M | |
| Total Other Income Expense Net | 3 M | 3.1 M | |
| Net Loss | -118.5 M | -112.6 M | |
| Income Tax Expense | 91.1 K | 95.7 K | |
| Net Loss | -116.5 M | -110.7 M | |
| Net Loss | -76.9 M | -80.8 M | |
| Interest Income | 5.2 M | 5.4 M | |
| Non Operating Income Net Other | 2.4 M | 2 M | |
| Net Interest Income | -604 K | -573.8 K | |
| Change To Netincome | 20.4 M | 10.7 M | |
| Net Loss | (2.19) | (2.30) | |
| Income Quality | 0.78 | 0.47 | |
| Net Income Per E B T | 0.88 | 0.80 |
Cara Profitability Driver Comparison
Profitability drivers are factors that can directly affect your investment outlook on Cara Therapeutic. Investors often realize that things won't turn out the way they predict. There are maybe way too many unforeseen events and contingencies during the holding period of Cara Therapeutic position where the market behavior may be hard to predict, tax policy changes, gold or oil price hikes, calamities change, and many others. The question is, are you prepared for these unexpected events? Although some of these situations are obviously beyond your control, you can still follow the important profit indicators to know where you should focus on when things like this occur. Below are some of the Cara Therapeutic's important profitability drivers and their relationship over time.
Use Cara Therapeutic in pair-trading
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Cara Therapeutic position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Cara Therapeutic will appreciate offsetting losses from the drop in the long position's value.Cara Therapeutic Pair Trading
Cara Therapeutic Pair Trading Analysis
The ability to find closely correlated positions to Cara Therapeutic could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Cara Therapeutic when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Cara Therapeutic - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Cara Therapeutic to buy it.
The correlation of Cara Therapeutic is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Cara Therapeutic moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Cara Therapeutic moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Cara Therapeutic can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Use Investing Themes to Complement your Cara Therapeutic position
In addition to having Cara Therapeutic in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Social Domain Thematic Idea Now
Social Domain
New or established large and mid-sized companies that are involved in the social media industry, including entities that provide web-based or mobile media applications and services across across large segment of population in multiple geographical areas. The Social Domain theme has 39 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Social Domain Theme or any other thematic opportunities.
| View All Next | Launch |
Check out Trending Equities. For information on how to trade Cara Stock refer to our How to Trade Cara Stock guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
To fully project Cara Therapeutic's future profitability, investors should examine all historical financial statements. These statements provide investors with a comprehensive snapshot of the financial position of Cara Therapeutic at a specified time, usually calculated after every quarter, six months, or one year. Three primary documents fall into the category of financial statements. These documents include Cara Therapeutic's income statement, its balance sheet, and the statement of cash flows.